3 Undervalued Stocks Primed for a 2X Return
For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in a shar...
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| 7.04 | |
| 7.05 | |
| - | |
| 7.24 | |
| 6.89 | |
| 1.28-16.24 | |
| 487 M | |
| 70 468 K | |
| 385 | |
| -0.58 | |
| 0.842 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in a shar...
Three equities stand out among the plethora of alternatives as possible Wall Street game-changers. Each represents a distinct industry: energy, cannabis and biotechnology. The first company is a shin...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: